Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingAlliance Health NC gene expression Coverage Update…
    Ask Trek AI about this page
    Modifiedalliance_health_ncPolicy 1S-11

    Genetic testing — gene expression (coverage criteria)

    Customize your policy alerts

    Sign up for alliance_health_nc Policy 1S-11 alerts

    Get alerted when Policy 1S-11 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicaid clinical coverage policy describing gene expression testing (definitions, coverage framework, and requirements) for beneficiaries enrolled in NC Medicaid PHPs. This part of the document provides background, definitions, and table-of-contents level structure affecting providers, labs, and prior authorization processes.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    Payeralliance_health_nc
    PolicyGenetic testing — gene expression (coverage criteria)
    Policy CodePolicy 1S-11
    Change TypeAdded AlloMapupdated non-coverage and codes
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review Date
    Key ActionObtain and document pre- and post-test genetic counseling and informed consent; submit prior approval and supporting records when requesting authorization or additional units.
    SourceLink
    POLICY UPDATE CHANGES

    Added coverage for AlloMap.

    Non-coverage criteria added for AlloMap.

    Procedure codes updated and code for AlloMap added.

    MedicaidProgram
    Jan 1, 2026Amendment date
    CLIALab certification
    Pre/PostGenetic counseling req.
    Not requiredPrior approval generally
    6Breast tests non-covered items

    Coverage Criteria and Clinical Indications

    Coverage framework (structure only)

    Policy sections outline when covered, specific criteria, Medicaid-specific criteria, and prior approval requirements.

    Document structure: Sections include: When Covered (3.0), General Criteria (3.1), Specific Criteria (3.2), Not Covered (4.0), Prior Approval (5.1), Prior Approval Requirements (5.2)

    Detailed coverage rules not present in this excerpt

    Breast cancer — general recurrence/chemo decision assays

    Covered when ALL of the following are met (Oncotype DX, EndoPredict, Prosigna, Breast Cancer Index, MammaPrint):

    Breast test general criteria: 1. Beneficiary underwent surgery and comprehensive pathological evaluation finalized; 2. Histology ductal, lobular, mixed, or metaplastic; 3. ER+ or PR+ or both; 4. HER2 negative; 5. pN0 or pN1mi (<=2 mm); 6. T1b–T3 (>0.5 cm and <=5.0 cm); 7. Beneficiary and provider are contemplating chemotherapy as a potential therapeutic approach; and 8. No additional gene expression profiling performed on same tumor or multiple sites when primary tumor multifocal.

    Exact assay list: Oncotype DX Breast Recurrence Score, EndoPredict, Prosigna, Breast Cancer Index, MammaPrint

    Oncotype DX — node-positive postmenopausal

    Covered when ALL of the following are met:

    Oncotype DX pN1 coverage: Postmenopausal individuals with 1–3 positive lymph nodes (pN1a–c) when criteria in Subsection 3.2.1(a)(1-4;6-8) are also met.

    Extended adjuvant hormonal therapy decision — EndoPredict/Prosigna/Breast Cancer Index

    Covered when ALL of the following are met:

    Extended therapy criteria general: 1. Criteria in Subsection 3.2.1(a)(1-6) met; 2. Oncotype DX Breast Recurrence Score was the initial gene expression test used; and 3. Beneficiary is a candidate for additional cancer therapy.

    Applies to EndoPredict, Prosigna, or Breast Cancer Index to aid decisions about extending adjuvant hormonal therapy beyond 5 years.

    Breast Cancer Index — extended therapy for node-positive

    Covered when ALL of the following are met:

    BCI node-positive extended therapy: 1. Criteria in Subsection 3.2.1(a)(1-4) met; 2. Oncotype DX was the initial test; and 3. Beneficiary is a candidate for additional hormonal or chemotherapy.

    Applies for beneficiaries with 1–3 positive lymph nodes.

    Thyroid nodule gene expression testing

    Covered when ALL of the following are met:

    Thyroid nodule criteria: 1. Beneficiary age >=21; 2. Thyroid nodule >=1 cm on ultrasound; 3. Uncertain cytology from initial FNA indicated by: atypia of undetermined significance; follicular lesion of undetermined significance; follicular neoplasm; suspicious for follicular neoplasm; or suspicious for malignancy.

    AlloMap — heart transplant rejection surveillance

    Covered when ALL of the following are met:

    AlloMap criteria: 1. Beneficiary age >=15; 2. At least two months (more than 55 days) post-transplant; 3. Used in conjunction with standard clinical assessment to identify stable recipients at low risk for moderate or severe acute cellular rejection.

    Additional universal requirements for all covered gene expression tests

    All covered gene expression profiling tests require ALL of the following:

    Universal test requirements: a. A certified genetic counselor or ordering provider shall evaluate and counsel the beneficiary pre- and post-test; b. Informed consent obtained prior to testing and beneficiary agrees to testing; c. Test must not be duplicative of another performed test; d. Test must be performed by a CLIA-certified laboratory; e. Test must be clinically valid, based on published peer-reviewed literature, and available for the suspected diagnosis; f. Test must be scientifically valid for identification of the specific genetically linked disease or condition.

    Refer to Subsections 1.1.5 and 6.2 for counseling reference.

    Not Medically Necessary / Specific Not Covered Indications

    Tests are not covered for the following specific situations

    Breast test non-coverage: Any of the following indications for gene expression profiling (Oncotype DX, EndoPredict, Prosigna, Breast Cancer Index, MammaPrint) are not covered when Section 3.0 criteria are not met: 1) to predict response to specific chemotherapy regimens; 2) beneficiary with known metastatic cancer; 3) DCIS as sole histology; 4) profiling same tumor or from more than one site when primary tumor is multifocal; 5) to determine risk when beneficiary has already decided to undergo or forego chemotherapy; 6) when a gene expression profiling test other than the listed assays is used.

    Derived from Section 4.2.1

    AlloMap non-coverage: AlloMap not covered for beneficiaries with history of antibody-mediated rejection; any use outside of heart transplant rejection monitoring; or when results would not impact clinical management (e.g., biopsy already planned).

    Derived from Section 4.2.1

    Thyroid testing non-coverage: Gene expression profiling tests for evaluation of a thyroid nodule are not covered when the criteria in Section 3.2.2 are not met.

    Derived from Section 4.2.1

    Covered with Criteria

    Covered when billed according to listed unit limits and frequency guidance:

    Breast cancer panels: CPT codes 81518-81523 are covered with a unit limitation of 1 per primary cancer occurrence.1 unit per primary cancer occurrence

    See chunk 55 for codes and limits.

    Thyroid cancer panels: CPT/PLA codes 81546, 0018U, 0026U, 0245U, 0287U are covered with a unit limitation of 1 per primary cancer occurrence.1 unit per primary cancer occurrence

    See chunk 56 for codes and limits.

    Transplant rejection monitoring: Code 81595 covered with specified monitoring frequency: monthly starting at 2 months post-transplant during first year; every 3-6 months in years 1-5 depending on stability; beyond 5 years as needed.timing-based intervals

    The policy Table of Contents identifies a When Not Covered section (Section 4.0) with subsections for General Criteria Not Covered (4.1) and Specific Criteria Not Covered (4.2, including 4.2.1 and 4.2.2). However, the excerpt provided contains only the section headings and structure; explicit exclusion condition text is present elsewhere in the policy and is summarized in the specific not-covered blocks below.

    Gene expression profiling is not covered to predict response to specific chemotherapy regimens, and is not covered for beneficiaries with known metastatic cancer. The policy also prohibits coverage when results would not affect clinical management (for example, if management decisions such as biopsy are already planned) and when the general Section 3.0 coverage criteria are not met. These limitations are listed under the policy's Specific Not Covered and General Not Covered subsections.

    Thyroid nodule gene expression testing is covered only when the criteria in Subsection 3.2.2 are met (including age ≥21 and an ultrasound nodule ≥1 cm with indeterminate cytology). The policy expressly states that thyroid nodule profiling is not covered when the Section 3.2.2 requirements are not satisfied.

    The policy excludes the use of breast gene expression profiling to manage Ductal Carcinoma in Situ (DCIS) when DCIS is the sole breast cancer histology. Gene expression assays listed for invasive disease are not intended to guide management when DCIS is the only histologic finding.

    The policy explicitly excludes using gene expression profiling to predict response to specific chemotherapy regimens. Such predictive use is identified as a non-covered indication for the listed breast prognostic assays (Oncotype DX, EndoPredict, Prosigna, Breast Cancer Index, MammaPrint) when Section 3.0 criteria are not met or when used for that purpose.

    When a procedure, product, or service does not have an assigned, specific CPT or HCPCS code, providers must report it with the appropriate unlisted procedure or service code and submit the required special report documentation per the current CPT/HCPCS instructions for use. The policy directs providers to follow CPT/HCPCS guidance for unlisted codes and supporting documentation.

    The policy includes a When Not Covered section (Section 4.0) that defines conditions under which services are considered not medically necessary. The policy instructs that detailed not-medically-necessary statements and examples are set out in that section and related subsections; providers should consult Section 4.0 for the full list of NMN conditions.

    Services are considered not medically necessary when the beneficiary fails to meet eligibility in Section 2.0, does not meet the coverage criteria in Section 3.0, when the service duplicates another provider's service, or when the procedure is experimental, investigational, or part of a clinical trial. The policy further specifies that tests are not medically necessary when results will not alter clinical management.

    The policy states that tests which would not impact clinical management are not covered as medically necessary. Examples include situations where a biopsy or other management step is already planned based on other clinical data; in such cases gene expression testing would not change the planned care and is therefore not covered.

    Covered Indications by Test and Use Case

    Claims, CPT/PLA, and Billing Rules

    Claims-related coding sections (ICD-10, CPT, Modifiers, Billing Units, Place of Service)mixed
    No codes listed
    Breast Cancer CPT Codes (unit limitations)CPTCovered
    81518CPT code listed in policy (breast cancer gene expression test)
    81519CPT code listed in policy (breast cancer gene expression test)
    81520CPT code listed in policy (breast cancer gene expression test)
    81521CPT code listed in policy (breast cancer gene expression test)
    81522CPT code listed in policy (breast cancer gene expression test)
    81523CPT code listed in policy (breast cancer gene expression test)
    Breast Cancer CPT CodesCPTCovered
    81518Listed breast cancer gene expression code
    81519Listed breast cancer gene expression code
    81520Listed breast cancer gene expression code
    81521Listed breast cancer gene expression code
    81522Listed breast cancer gene expression code
    81523Listed breast cancer gene expression code
    Thyroid Cancer CPT/PLA CodesmixedCovered
    81546Thyroid cancer gene expression CPT code
    0018UThyroid cancer PLA code
    0026UThyroid cancer PLA code
    0245UThyroid cancer PLA code
    0287UThyroid cancer PLA code
    Transplant MonitoringCPTCovered
    81595Transplant rejection monitoring gene expression code
    Genetic CounselingCPTCovered
    96041Medical geneticist or genetic counselor counseling; 1 unit = 30 minutes
    Unlisted Procedure or ServiceCPT
    Unlisted CPT/HCPCSUse appropriate unlisted procedure or service code when no specific code exists and provide special report per current CPT/HCPCS instructions
    Unit limitation per primary cancer occurrence
    Unit limitation ruleOnce each primary cancer occurrence (applies to listed breast cancer gene expression CPT codes)
    Applies to codesCPT 81518, 81519, 81520, 81521, 81522, 81523
    Operational noteProviders must follow the unit limitation when billing and seek prior approval only if requesting additional units beyond this limit
    Breast cancer unit limit per primary occurrence
    Breast cancer unit limit1 unit per primary cancer occurrence

    Provider Responsibilities, Prior Authorization, and Documentation

    Prior Authorization

    Prior approval required when exceeding Attachment A limits

    Prior approval is required when exceeding unit limitations found in Attachment A, Section C; providers must follow the prior approval requirements documented in Subsection 5.2 and submit the prior approval request and supporting health records to the DHHS Utilization Review Contractor.

    • Submit the prior approval request and all health records supporting that the beneficiary meets the specific criteria in Subsection 3.2.
    Prior Authorization

    EPSDT does not waive prior approval

    If a service requires prior approval, EPSDT does not waive that requirement for beneficiaries under age 21; the ordering provider must ensure prior approval is obtained when applicable and counseling/consent are documented.

    • EPSDT does not eliminate prior approval requirements; see NCTracks and EPSDT resources for additional guidance.

    Beneficiary and Test Eligibility Requirements

    When requesting services, providers must include supporting clinical documentation. Specifically, if additional testing units are requested beyond standard limits, providers should submit prior related laboratory results and rationale demonstrating how the additional results will alter clinical management and improve outcomes; these prior results serve as supporting documentation for the authorization request.

    Definitions and Background

    Gene expression describes the process by which genetic information is transcribed into RNA and proteins, functioning as on/off switches and modulators of the timing, location, and amount of gene products. Assessing gene expression evaluates the functional activity of gene products or associated phenotypes and is clinically relevant in conditions such as cancer where markers like ER, PR, and HER2 inform treatment decisions.

    inv-51: Definition — Adjuvant Therapy
    DefinitionAdditional treatment given after the primary treatment (such as surgery or radiation) intended to eliminate remaining cancer cells or reduce the risk of recurrence
    PurposeImprove long-term outcomes and enhance chances of cure or disease control
    Typical useOften used in conjunction with primary treatment to provide comprehensive management
    inv-52: Definition — Estrogen Receptor (ER)
    Definition

    Not Covered / Exclusions

    The policy's Not Covered section (Section 4.0) includes both general and specific non-coverage lists and identifies Medicaid-specific additional criteria not covered (Subsections 4.2, 4.2.1, and 4.2.2). The excerpt provides the structure and specific statements for many exclusions and also instructs the use of unlisted codes where no specific CPT/HCPCS code exists.

    Specific non-covered indications include using gene expression tests to predict response to particular chemotherapy regimens, performing testing for beneficiaries with known metastatic cancer, using gene expression profiling when DCIS is the sole breast histology, duplicate or multisite testing of the same tumor, and investigational or otherwise unsupported uses. These non-coverage rules apply to the listed breast prognostic assays and AlloMap where noted.

    The policy reiterates that breast gene expression profiling is not covered to predict response to specific chemotherapy regimens, is not covered for known metastatic disease, and is specifically excluded when DCIS is the only histology. Duplicate testing or testing of multiple sites for a multifocal primary is also not covered, as are uses that would not change clinical management.

    The Not Covered section does not provide an exhaustive enumeration of every possible test that might be excluded; rather, it lists the specific non-covered indications. When no specific CPT or HCPCS code exists for a service, the policy requires use of the appropriate unlisted code and submission of the special report per CPT/HCPCS instructions to support adjudication.

    Policy Summary
    Payeralliance_health_nc
    PolicyGenetic testing — gene expression (coverage criteria)
    Policy CodePolicy 1S-11
    Change TypeAdded AlloMapupdated non-coverage and codes
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review Date
    Key ActionObtain and document pre- and post-test genetic counseling and informed consent; submit prior approval and supporting records when requesting authorization or additional units.
    SourceLink
    On This Page
    Coverage Criteria and Clinical IndicationsCovered Indications by Test and Use CaseClaims, CPT/PLA, and Billing RulesProvider Responsibilities, Prior Authorization, and DocumentationBeneficiary and Test Eligibility RequirementsDefinitions and BackgroundNot Covered / Exclusions

    See chunk 57 for schedule.

    Genetic counseling: CPT 96041 covered with a limitation of 3 units (90 minutes) total.3 units (90 minutes)

    See chunk 58.

    Covered CPT codes (breast)81518, 81519, 81520, 81521, 81522, 81523
    Billing guidanceEach listed code is limited to a single unit for each primary breast cancer occurrence; document clinical indication in the record
    Thyroid cancer unit limit per primary occurrence
    Thyroid cancer unit limit1 unit per primary cancer occurrence
    Covered CPT/PLA codes (thyroid)81546, 0018U, 0026U, 0245U, 0287U
    Billing guidanceEach listed thyroid code is limited to one unit per primary cancer occurrence; include relevant FNA/cytology and ultrasound documentation
    Genetic counseling unit limit
    Genetic counseling unit limit3 units (90 minutes total; 1 unit = 30 minutes)
    CPT code96041
    Documentation requirementWhen billed, document pre- and post-test counseling, informed consent, and counseling elements in the beneficiary's health record
    Provider qualification noteMay be provided by a certified genetic counselor or by a licensed provider when a certified counselor is not available (document qualifications)
    Prior Authorization

    Prior approval required for requests exceeding Attachment A unit limits

    Prior approval is not required generally for gene expression profiling tests, but prior approval is required when requesting services that exceed the unit limitations in Attachment A, Section C.

    • When requesting additional units beyond the listed unit limits, follow Subsection 5.2 and provide supporting documentation per Subsection 5.3.2.
    Billing Rule

    Follow Attachment A unit limits and frequency guidance

    Providers must follow the unit limitations and frequency guidance for the listed CPT/PLA codes in Attachment A when billing gene expression tests; requests for additional units must be justified per the documentation requirements.

    • Breast panels (CPT 81518–81523): 1 unit once per primary cancer occurrence.
    • Thyroid panels (81546, 0018U, 0026U, 0245U, 0287U): 1 unit once per primary cancer occurrence.
    • Transplant monitoring (81595): specified intervals (monthly starting at 2 months post-transplant in year 1; every 3–6 months in years 1–5; beyond 5 years as needed).
    • Genetic counseling (96041): limited to 3 units (90 minutes).
    Note
    Note
    Step Therapy

    No step therapy specified; follow transplant monitoring intervals for 81595

    No step therapy is specified in this portion of the policy; transplant rejection monitoring (CPT 81595) uses defined monitoring intervals rather than stepwise therapy requirements.

    • Policy states no step therapy is specified for gene expression profiling tests.
    • Use the monitoring schedule for 81595 (see Attachment A) to guide ongoing testing post-transplant.
    Step Therapy

    Follow specified AlloMap monitoring intervals (81595)

    Transplant rejection monitoring with AlloMap (CPT 81595) must follow the specified post-transplant monitoring schedule: monthly starting at >55 days (≈2 months) post-transplant in the first year, then every 3–6 months in years 1–5 depending on stability, and thereafter as clinically indicated.

    • Do not use AlloMap outside the validated heart transplant rejection monitoring indications (see non-coverage rules).
    Documentation Required

    Document genetic counseling elements and informed consent

    When genetic counseling is provided by a licensed provider instead of a certified genetic counselor, the provider must document counseling elements and informed consent in the beneficiary's health record as described in the genetic counseling definition.

    • Document structured family medical and genetic history, multi-generation pedigree, analysis for genetic risk assessment, discussion of natural history and recurrence risk, testing/screening/monitoring options, and that informed consent was obtained.
    Documentation Required

    Document counseling, consent, non-duplication, and EPSDT justification

    Providers must document pre- and post-test genetic counseling, documented informed consent, and that the test is not duplicative; for beneficiaries under 21, EPSDT requirements do not waive prior approval and documentation must support medical necessity.

    • Maintain records showing counseling occurred, informed consent was obtained, and the test is not a duplicate of another performed test.
    • For additional units or EPSDT exceptions, include prior related lab results and justification per Subsection 5.3.2.
    Prior Authorization

    Submit prior approval request with full supporting documentation

    For prior approval requests, submit the prior approval request plus all health records and supporting documentation that the beneficiary meets the criteria in Subsection 3.2; when requesting additional units, include the reason for the test, previous related lab results, how results improve outcomes, and how results alter treatment.

    • Include clinical records and any prior test results demonstrating indications and how results will affect management.
    Billing Rule

    Use unlisted code + special report when no specific code exists

    When no specific CPT or HCPCS code exists, providers must report the service with the appropriate unlisted procedure or service code and comply with CPT/HCPCS instructions for unlisted codes, including submission of the required special report documentation.

    • Follow the Instructions for Use in the current CPT and HCPCS editions for unlisted procedure or service codes and submit a special report as required.
    Note
    Denial Risk

    Prior approval referenced — lack of required prior approval may cause denial

    Prior approval is referenced as a requirement area; services lacking required prior approval (when exceeding Attachment A limits) may be subject to denial.

    • Verify whether the requested service exceeds Attachment A unit limits and obtain prior approval if required.
    Denial Risk

    General denial triggers — eligibility, criteria, duplication, experimental

    Services are not covered when the beneficiary does not meet eligibility (Section 2.0), does not meet the coverage criteria (Section 3.0), the service duplicates another provider's service, or the service is experimental/investigational.

    • Confirm beneficiary eligibility and that all Section 3.0/Subsection 3.2 criteria are met before ordering.
    Denial Risk

    Specific denial triggers — listed non-covered indications

    Specific denial triggers include use of gene expression profiling to predict response to specific chemotherapy regimens, testing in beneficiaries with known metastatic cancer, duplicate or multisite testing of the same tumor, testing when results would not change chemotherapy decisions, and use of assays outside the listed approved tests.

    • Avoid ordering tests for the listed non-covered indications to prevent claim denial.
    Denial Risk

    Non-covered indications for breast gene expression tests

    Breast gene expression tests (Oncotype DX, EndoPredict, Prosigna, Breast Cancer Index, MammaPrint) are not covered when used to predict response to specific chemotherapy regimens, for beneficiaries with known metastatic cancer, when DCIS is the sole histology, for testing the same tumor or multiple sites in multifocal primaries, when results will not affect chemotherapy decisions, or when a different, unlisted gene expression test is used.

    • Do not order these breast assays for the enumerated non-covered indications.
    Denial Risk

    Non-covered indications for AlloMap

    AlloMap is not covered for beneficiaries with a history of antibody-mediated rejection, for any use outside heart transplant rejection monitoring, or when results would not impact clinical management (for example, when a biopsy is already planned).

    • Do not use AlloMap for antibody-mediated rejection surveillance or non-transplant indications; follow coverage criteria in Subsection 3.2.1 for appropriate use.
    Denial Risk

    Non-covered indications for thyroid gene expression tests when Section 3.2.2 criteria unmet

    Thyroid nodule gene expression profiling is not covered when the specific criteria in Section 3.2.2 are not met (e.g., beneficiary age, nodule size, and indeterminate cytology requirements).

    • Ensure all Section 3.2.2 criteria are documented before ordering thyroid gene expression tests.
    Billing Rule

    Report the most specific CPT/HCPCS code; use unlisted code + special report if none

    Providers shall report the most specific CPT or HCPCS code that accurately and completely describes the procedure, product, or service provided; failure to do so may affect payment and claims processing.

    • Use the current CPT, HCPCS, and UB-04 Data Specifications Manual editions in effect at time of service.
    • If no specific code exists, report the service with the appropriate unlisted code and include a special report.
    Estrogen receptor (ER) is a protein that responds to estrogen and influences cell growth and gene expression
    Clinical relevanceER status is relevant in cancer treatment decisions and hormone therapies
    Role in testingUsed as a biomarker informing gene expression test interpretations
    inv-53: Definition — Genetics
    DefinitionGenetics involves investigating the impact of genes on an individual's characteristics and traits
    ScopeIncludes study of hereditary and molecular contributions to disease
    ApplicationUnderpins genetic testing and counseling processes referenced in this policy
    inv-54: Definition — Genetic Counselor
    DefinitionGenetic counselors are health professionals with specialized education, training, and experience in medical genetics and counseling
    CertificationCertified by the American Board of Genetic Counseling or have Active Candidate Status
    FunctionAssist beneficiaries in understanding and adapting to genetic contributions to disease
    inv-55: Definition — Genetic Counseling
    DefinitionGenetic counseling is a process of communication to enable informed medical decisions, including structured family history, multi‑generation pedigree, genetic risk assessment, and counseling on natural history, recurrence risk, and testing options
    Provider provisionMay be provided by a licensed provider when no certified genetic counselor is available, with required documentation of counseling elements and informed consent
    Documentation elementsLikelihood of disease, impact, possibility of modification, anticipated future developments, and documented informed consent after beneficiary understanding
    inv-56: Definition — Genomics
    DefinitionGenomics is the study of the entirety of a person's DNA (the genome), including its structure, function, mapping, and evolution
    ScopeEncompasses genes and broader genomic investigations relevant to clinical testing
    Relation to policyProvides foundational context for gene expression and molecular testing covered by this policy
    inv-57: Definition — Histology
    DefinitionHistology is the study of tissues focusing on their microscopic structure and composition
    Clinical useHistologic classification informs eligibility for certain gene expression tests in this policy
    ExamplesIncludes ductal, lobular, mixed, and metaplastic histologies referenced elsewhere in the policy
    inv-58: Definition — Hormonal Therapy
    DefinitionHormonal therapy is a treatment that modifies hormone levels or activity to manage hormone‑sensitive conditions such as certain cancers
    Clinical roleUsed as adjuvant or extended therapy decisions informed by gene expression assays
    Relation to testsAssays may guide decisions about extending hormonal therapy beyond initial treatment period
    inv-59: Definition — HER2
    DefinitionHER2 (Human Epidermal Growth Factor Receptor 2) is a protein receptor that influences cell growth and is used as a biomarker in cancer diagnosis and treatment decisions
    Clinical relevanceHER2 status is part of eligibility criteria for certain breast gene expression tests (e.g., HER2 negative requirement)
    Role in testingHelps stratify tumor biology for prognostic assays
    inv-60: Definition — Hormonal Therapy (duplicate inventory entry)
    DefinitionHormonal therapy is a treatment that modifies hormone levels or activity to manage hormone‑sensitive conditions, such as certain cancers
    Synonym noteSee duplicate definition in policy (1.1.8) for same concept
    Clinical useRelevant to decisions about adjuvant or extended therapy guided by assays
    inv-61: Definition — HER2 (duplicate inventory entry)
    DefinitionHER2 (Human Epidermal Growth Factor Receptor 2) is a protein receptor influencing cell growth and used as a biomarker in cancer diagnosis and treatment decisions
    Synonym noteDuplicate entry of HER2 definition in policy (1.1.9)
    Clinical implicationUsed alongside ER and PR status to inform eligibility for gene expression testing
    inv-62: Definition — Primary Cancer
    DefinitionPrimary cancer refers to the initial site where a cancerous tumor originates before potential spread
    Usage in policyUnit limitations for gene expression tests are specified per primary cancer occurrence
    ImplicationMultiple tests may be limited when dealing with multifocal primaries or separate primary occurrences
    inv-63: Definition — Progesterone Receptor (PR)
    DefinitionProgesterone receptor (PR) is a protein that responds to progesterone and regulates gene expression and cellular functions
    Clinical relevancePR status may affect eligibility for breast gene expression assays
    Relation to EROften considered alongside ER and HER2 for tumor biomarker profiling
    inv-64: Definition — Breast gene expression assays (list of named assays)
    Named breast gene expression assaysOncotype DX Breast Recurrence Score; EndoPredict; Prosigna (Breast Cancer Prognostic Gene Signature Assay); Breast Cancer Index; MammaPrint
    Use caseReferenced as the approved assays for breast prognostic/recurrence risk testing in this policy
    Non‑substitutable noteUse of a gene expression profiling test other than these listed assays is not covered for the indicated breast cancer uses
    inv-65: Definition — AlloMap
    DefinitionAlloMap is a gene expression profiling test intended for heart transplant rejection monitoring
    LimitationsNot validated for antibody‑mediated rejection or uses outside heart transplant rejection monitoring
    Policy changeAlloMap was added to covered tests effective 01/01/2026 (see policy history)
    inv-66: Definition — Unlisted Procedure or Service
    DefinitionUnlisted procedure or service: procedures, products, or services without a specific CPT/HCPCS code must be reported using the appropriate unlisted code and comply with current CPT/HCPCS instructions including submission of a special report
    Billing requirementProviders shall report the most specific billing code available; if none exists, use the appropriate unlisted code per current CPT/HCPCS guidance
    Documentation requirementWhen using unlisted codes, providers must submit the required special report per current code edition